Introduction
The use of adenoviruses as virus vectors in vaccination trials is becoming more and more frequent. Two strategies may be used to construct these viruses. One of these is to clone foreign genes into regions which are dispensable for virus replication, like the E3 gene, or between E4 and the right inverted terminal repeat (ITR) (Prevec et al., 1989 (Prevec et al., , 1990 (Prevec et al., , 1991 Vernon et al., 1991; Charlton et al., 1992; Caravokyri et al., 1993; Jacobs, 1993; Natuk et al., 1993 ; Wesseling et aL, 1993; Zheng et al., 1993; Chengalvala et al., 1994) . This approach leads to replication-competent viruses. These vector-based vaccines proved to be protective even when low doses of viruses were used. Nevertheless, the biosafety of such constructs is questionable, as the recombinant virus can be excreted into the environment (Oualikene e t al., 1994) .
The other strategy is to clone foreign genes in the left part of the virus genome, deleting the E1A and, in certain cases, the E1B promoters and coding regions (Adam et al., 1994; Ballay et al., 1987; Eloit et al., 1990; Ragot et al., 1993) . The E1A transcription unit encodes four polypeptides expressed in the early phase of infection, which are able to transactivate other adenovirus early genes (Elb, E2, E3 and E4) and even cellular promoters. The transactivation properties of the E 1A gene products are mainly dependent on a domain of 46 amino acids, located in the 289 amino acid-long polypeptide (for a review see Nevins, 1990) . These E1A-deleted viruses are unable to replicate in cells which do not complement the defective gene but are still able to induce the synthesis of very high levels of the foreign protein when cells are infected at high m.o.i. (Ballay et al., 1987; Eloit et al., 1990; Ragot et al., 1991) . These viruses have been used as efficient vectors for gene therapy (for a review see Gerard & Meidell, 1993) and vaccination. The drawback of such an approach is that a high amount of viruses 0001-3169 © 1995 SGM must be injected into animals to elicit a strong immune response.
The choice between replicative versus non-replicative vectors is of general interest for vaccinating humans and animals. The demonstration of the efficiency of the injection of naked plasmid DNA in eliciting protective B and T cell responses (Ulmer et al., 1993) indicates that the use of replication-competent viruses should be unnecessary. For poxvirus vectors, it has been demonstrated that canarypoxvirus, which is unable to replicate productively in mammal cells, was as efficient as the vaccinia virus (i.e., the protective doses were similar). In contrast, the results obtained with another avian poxvirus, the fowlpox virus, showed that a 100-fold higher dose than that of vaccinia virus was necessary (Taylor et al., 1992) . Nevertheless, these results were obtained with different poxviruses and not with identical viruses differing by selected gene deletions. These results can be explained by many factors, including the use of different cell lines for virus titration and a lack of similarity between the efficiency of the first steps of virus infection.
To obtain information on this topic, we have chosen to compare the efficiency of adenoviruses type 5, E1A defective or non-defective, as virus vectors. To do so, similar viruses expressing the same gene [gD from pseudorabies virus (PRV) under the control of the major late promoter (MLP) from adenovirus type 2] were compared for in vitro growth properties and vaccine efficiency. The glycoprotein gD (formerly referred as gp50) is a strong immunogen of PRV, which is able to induce a protective immune response against challenge in several animal species (Marchioli et al., 1987; Eloit et al., 1988; Ishii et al., 1988) . The defective virus (Ad-gD) was previously described (Eloit et al., 1990) . The nondefective virus (Ad-gD-E1A) was constructed by replacing a functional E1A gene in the virus genome in an ectopic position, in such a way that the E1A promoter was far from its enhancer sequences. We show in this report that, in contrast to Ad-gD, Ad-gD-E1A was able to replicate in Vero cells, but less efficiently than the wildtype virus. This property was possibly related to the ectopic position of the E1A gene. In mice (a nonpermissive species) or in cotton rats (a permissive species), the two viruses elicited similar antibody responses against gD. Nevertheless, while both viruses gave the same high level of protection against a severe challenge, the protective dose of Ad-gD-E 1A was slightly lower in mice (20-fold) and far lower in cotton rats (at least 250-fold) than that of Ad-gD.
Methods
Celh" and viruses. Recombinant adenoviruses were obtained by DNA transfection, then amplified and titrated in 293 cells (Graham et al., 1977) as previously described (Eloit et al., 1990) . Ad-gD, previously identified as Ad-gp50, was constructed from d1327, an E3-deleted mutant of Ad5 (Eloit et al., 1990) . The Kojnok strain of PRV was grown and titrated in PK15 cells. Vero cells were maintained as described (Eloit et al., 1990) .
Plasmids. The plasmid pE1A-Ad5 was a gift from M. Perricaudet (Institut Gustave Roussy, Villejuif, France). It contains the nucleotides 0-1771 from the left part of Ad5 genome, including the E1A transcription unit. The plasmid pMLP-gD has been described previously (referenced as pMLP-gp50-6) (Eloit et al., 1990) . It contains nucleotides 1-455 of Ad5 genome, carrying the ITR, the encapsidation signal sequences and the enhancer of the E1A promoter, followed by the MLP of Ad2 and its three leader sequences (nucleotides 6041-6080; 7100-7170; 9635 9725), the gD (gp50) gene of PRV and the polyadenylation signal of the simian virus 40 (SV40) A gene (nucleotides 2770-2553).
Kinetics of virus multiplication in cell culture. Vero cells and 293 cells
were infected at different m.o.i. The virus suspension was left for 1 h in contact with the cells at 37 °C, then discarded. The cell layers were rinsed with flesh medium, then the same volume of culture medium was added to each well of the plates and the cultures were incubated for a definite time. The virus was then released from the pool of the cells and the medium by three cycles of freezing and thawing, clarified by lowspeed centrifugation and titrated in 293 cells. Virus titres were expressed in TCID~0/ml.
Vaccination and challenge of mice and cotton rats.
Recombinant adenoviruses were purified twice by banding in CsC1 to avoid carrying over small amounts of cell-associated gD. Vaccine doses were prepared by diluting virus stocks in cold tissue culture medium. Animals were vaccinated once by the intramuscular route, with vaccine doses ranging from 10 ~ TCIDs0 to 109 TCIDs0, in a volume of 100 ~tl. Animals were challenged 5 weeks after vaccination intraperitoneally with 200 I~1 of tissue culture medium containing 20 LDs0 of the PRV Kojnok strain, previously titrated in the target species. This challenge dose corresponds to 10 zs and 10 31 TCID~, respectively for mice and cotton rats. Animals were then observed daily for 15 days. The 50% protective doses (PDs0) were estimated by regression analysis of protection rates after logit transformation using the SAS software (SAS, 1989) . When all the animals were protected even at the lowest dose used, a minimum PDs0 was calculated by using a slope of the regression curve equal to the mean of the slopes of the other groups.
Titration ofgD antibodies. Blood from each animal was collected at the time of challenge. Sera from animals of each group were pooled and antibodies against gD were titrated by ELISA as previously described (Eloit et al., 1990) with the following modifications: sera were diluted in PBS pH 7.2, 0.05 % Tween 20, 0.5% gelatin; biotin-labelled antimouse (Biosis) or anti-rat (Nordic) IgG was used as the conjugate; all incubations were made at 37 °C. . . . . . . . . . . . . . . . . . . . . . . . . .  tm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IAd-gD-E1A gene, between the ClaI and the XbaI sites, thus giving pMLP-gD-E1A. This plasmid was digested with PstI and ClaI and ligated at the unique ClaI site of d1327 in the E1A coding region, so restoring a functional E1A transcription unit. Ad-gD and Ad-gD-E1A are then isogenic, except for the E1A gene. The ability of Ad-gD-E1A to drive the synthesis of gD in cell culture was confirmed by western-blotting (not shown).
Results

Construction of Ad-gD-EIA
Kinetics of virus multiplication in cell culture
Ad-gD, Ad-gD-E1A and Ad5-wt (wild-type) showed identical growth kinetics in 293 cells, which synthesizes the E1A gene products (Fig. 2) . In contrast, these kinetics were different in Vero cells (Fig. 2) . As expected, Ad-gD did not show any evidence of virus replication. Ad-gD-E1A grew as well as the wild-type virus when cells were infected at high (10 TCIDs0/cell ) or medium (1 TCIDso/cell ) m.o.i. At low m.o.i. (0.1 TCID~o/cell ), the replication of Ad-gD-E1A was far lower than that of wild-type Ad5.
Antibody response against gD in mice and cotton rats
Antibody response against gD was tested at the time of challenge, 5 weeks after inoculation of the recombinant adenoviruses (Table 1) . Because two different conjugates were used to develop the ELISA tests in mice and cotton rats, it is only possible to compare antibody titres within each species. For each animal species, the antibody titres were similar for Ad-gD and Ad-gD-E1A for each dose tested. Even in cotton rats, no clear disadvantage of using a replication-defective virus could be demonstrated. 
Protection against challenge of cotton rats and mice
Both in mice and cotton rats, the two viruses were able to confer a high level of protection against the challenge. Nevertheless, virus titres necessary to achieve protection were very different. In cotton rats, the lowest tested dose of Ad-gD-E1A (105 TCIDs0 ) protected all the animals (Table 1) . In this species, the estimated PDso was inferior or equal to 103.5 TCIDso, at least 250-fold lower than that of Ad-gD (1061 TCID~0). In mice, PDs0 of Ad-gD-E1A (106~ TCIDs0 ) was not significantly different from that of Ad-gD (107.7 TC1D50). Analysis of individual antibody titres of mice inoculated with 109 and 108 TCID~0 of Ad-gD showed that there was no correlation between IP: 54.70.40.11
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Defective and non-defective adenovirus vectors 1587 antibody titres and resistance against the challenge. All dead mice had a titre ranging from 128 to 1024 at the time of challenge, whereas 4/17 mice surviving the challenge had titres lower than or equal to 128 (i.e. < 8, 8, 16, 128) .
Discussion
Ad5-based vaccines have been tested for human and veterinary applications. Some species are fully or partly permissive to Ad5 infection (human, pig, cotton rat and other) as judged by inoculation trials of animals or cell lines from the corresponding species. Others seem to be only weak or non-permissive (mice, cats) (Betts et al., 1962; Prevec et al., 1989; Prince et al., 1993; Oualikene et al., 1994) . We have recently shown that cotton rats could be considered as fully permissive when inoculated by the muscular route, whereas mice showed evidence of only a low level of virus replication in the same conditions (Oualikene et aL, 1994) . So we chose to investigate the comparative efficiency of the two recombinant viruses as vaccine vectors in these two species, which both develop a lethal disease after a PRV challenge. This report is, to our knowledge, the first comparison of the efficiency of isogenic virus vectors differing only by their capacity to replicate in the target species. Ad-gD-E1A was obtained by rescuing the E1A transcription unit in Ad-gD, an E1A deletion mutant of d1327 expressing the gD glycoprotein of PRV. We have shown that Ad-gD-E1A grew as well as the wild-type virus in non-transcomplementing Vero cells when they were infected at medium or high m.o.i., but to a lesser extent at a low m.o.i. For the construction of this virus, the rescued E1A gene was located in an ectopic position, far from its enhancer sequences. We did not try to quantify the level of expression of E1A early after infection. However, it can be tentatively speculated that locating E1A far from its enhancer sequences may lead to a lesser expression of the E1A gene products early after infection, which could be the cause of the low efficiency of plating of this virus at low m.o.i. The correlation between the level of expression of E1A and the level of transactivation of other early adenovirus genes is controversial. Results of experiments using adenoviruses in which E1A expression was driven by heterologous promoters suggested that low levels of E 1A protein were sufficient to obtain the same level of virus production as that of wild-type virus (Hitt & Graham, 1990) . However, these results were obtained at high m.o.i. (10 p.f.u./cell). Nevertheless, other experiments, conducted at the RNA level, showed a relation between the level of E 1A proteins and the level of transcription by target promoters (Brunet & Berk, 1988) .
The first conclusion which can be drawn from the protection assays is that the two viruses were able to confer a strong immunity in these two species. However, there was a clear difference concerning PDs0. In cotton rats, there was at least a 250-fold difference between non-defective and defective viruses. Because we have shown that wild-type Ad5 could be isolated from lungs and nasal washes after intramuscular inoculation of cotton rats (Oualikene et al., 1994) , we conclude that, in permissive species like humans, the choice between the two vectors relies upon a decision between use of low vaccine dose and biosafety. However, we cannot exclude the possibility that viruses constructed like Ad-gD-E1A may have a more restricted pattern of dissemination in the body than wild-type Ad5, because of their lower replication efficiency in cell culture at low m.o.i. In fact, after intramuscular inoculation of cotton rats, this virus was not isolated from the lungs, as opposed to wild-type Ad5 (not shown). This potentially interesting feature remains to be studied further. Other comparative properties of the two viruses have not been investigated, like the lag between vaccination and development of a protective response, the duration of immunity and the comparative efficiency for other routes of vaccination. Nevertheless, preliminary experiments show that a dose of 10 9 TCIDs0 of Ad-gD was able to fully protect mice as early as 15 days post-inoculation and for a period of at least 6 months (unpublished results of ongoing experiments).
Results obtained in mice showed that the PDs0 of Ad-gD-E1A was 20-fold lower than that of Ad-gD. This was not unexpected as we have previously shown that mice support a low level of replication of wild-type Ad5 (Oualikene et al., 1994) . However, diffusion of the virus was restricted to local lymph nodes after intramuscular inoculation, unlike after intranasal administration where the virus diffusion was wider. Paradoxically, the use of replication competent Ad5 in certain non-or semipermissive species, at least by the muscular route, may be a good choice associating use of lower doses and biosafety. Nevertheless, risks of oncogenic properties of Ad5 expressing E1A in non-permissive species or low levels of E1A in permissive species (Herbst et al., 1990) must be kept in mind and studied case by case.
The difference between the PDs0 of the two viruses was not related to their ability to induce antibodies against gD. On the contrary, similar antibody titres were induced by the two viruses within each species. We have previously shown (Eloit et al., 1990 ) that Ad-gD was able to induce the progressive accumulation of at least the same level of gD in cells which do not provide a phenotypic complementation to the E1A gene as in cells expressing the E1A gene products (293 cells). Nevertheless, the synthesis of gD was faster but short-lived (due to the death of the cells) in 293 cells. Experiments with adenoviruses expressing or not expressing the E1A gene which were constructed in a similar way to that reported here also showed no significative advantage of using replicative adenoviruses to express foreign genes in cell culture. Nevertheless, the comparison of their efficiency in animals was not investigated (Levrero et al., 1991) . It is therefore possible that a long-lasting presentation of gD to the immune system by Ad-gD can compensate for the lack of replication of the virus.
The lack of correlation between antibody titres against gD and protection which is apparent in this work has been previously reported for pigs (Eloit et al., 1992) and mice (Ganne et al., 1993) . It is probable that gD is able to induce a cytotoxic T cell response, like its bovine herpesvirus 1 counterpart (Martine Denis, personal communication). For reasons that remain unclear, this cell-mediated immunity seems to be induced at lower doses by the replication-competent virus than by the replication defective one, in contrast to the production of specific antibodies.
Taken as a whole, our results clearly show that Ad5based vaccine protective doses are strictly linked to the capacity of replication of the virus, at least for the model we have used (gD of PRV). This difference between the two viruses is not dependent on their capacity to generate a specific antibody response but seems mainly linked to their ability to induce a cell-mediated immunity. This suggests that the choice between replication defective or competent vectors could be different according to the target disease.
